Clinical trial

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

NCT00448279

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record trastuzumab Normalized identity: trastuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Chemotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-04-01

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

trastuzumabDRUG · verified · RxNorm: trastuzumab

ChemotherapyDRUG

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

RomaItaly2 NaplesItaly1 GenovaItaly1 PadovaItaly1 FlorenceItaly1 PaviaItaly1 BresciaItaly1 TorinoItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00448279 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.